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Abstract.
Background: Duchenne muscular dystrophy (DMD) is a progressive muscle disease. No curative therapy is currently available,
but in recent decades standards of care have improved. These improvements include the use of corticosteroids and mechanical
ventilation.
Objective: To present a detailed population based report of the DMD disease course in The Netherlands (1980–2006) and
evaluate the effect of changes in care by comparing it with an historical Dutch DMD cohort (1961–1974).
Methods: Information about DMD patients was gathered through the Dutch Dystrophinopathy Database using a standardized
questionnaire and information from treating physicians.
∗Correspondence to: J.C. van den Bergen, MD Department of
Neurology, K5-Q-110 Leiden University Medical Center Albinus-
dreef 2, 2333 ZA Leiden, The Netherlands. Tel.: +31 71 5262197;
Fax: +31 71 5268253; E-mail: j.c.van den bergen@lumc.nl.
ISSN 2214-3599/14/$27.50 © 2014 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License.
100 J.C. van den Bergen et al. / Duchenne Muscular Dystrophy in The Netherlands
Results:The study population involved 336 DMD patients (70% of the estimated prevalence), of whom 285 were still alive. Mean
age at disease milestones was: diagnosis 4.3 years, wheelchair dependence 9.7 years, scoliosis surgery 14 years, cardiomyopathy
(fractional shortening <27%) 15 years, mechanical ventilation 17 years and death 19 years. Within our cohort, corticosteroid use
was associated with an increased age of wheelchair dependence from 9.8 to 11.6 years (p < 0.001). When comparing the recent
cohort to the historical cohort, mean survival improved from 17 to 27 years (p < 0.001).
Conclusion: The current study gives detailed information about the disease course of DMD patients, provides evidence for the
positive effect of steroid treatment and mechanical ventilation and supports the use of patient registries as a valuable resource
for evaluating improvements in care.
Keywords: Duchenne muscular dystrophy, natural history, corticosteroids, mechanical home ventilation, survival
INTRODUCTION
Duchenne muscular dystrophy (DMD) is an
X-linked progressive muscle disease affecting approx-
imately 1:4700 boys [1]. Symptoms generally appear
at the age of 2–4 years, when affected boys have fre-
quent falls and show difficulty in rising from the floor
and walking stairs. Weakness slowly progresses, lead-
ing to wheelchair dependence, loss of upper extremity
function, development of scoliosis, cardiac and ven-
tilatory problems. The main causes of death in DMD
patients are respiratory and cardiac failure.
Currently, no curative treatment for DMD is
available. However, in the last decades significant
improvements have been made in the care for DMD
patients, improving both quality of life and life
expectancy. These changes include the prescription
of corticosteroids, the use of cough support and
mechanical ventilation, cardiac medication, and sev-
eral rehabilitation treatments, like splints, airstacking
and training. Over the last decades there has been
increasing evidence to support these measures. Steroid
trials have shown a significant decrease in rate of dis-
ease progression as measured by muscle strength and
functional tests [2–4]. Several observational studies
have further strengthened the evidence for use of cor-
ticosteroids by showing a delay in the age at loss of
ambulation, decrease in the number of patients need-
ing scoliosis surgery and attenuation of the decline in
respiratory function [5–11]. Use of mechanical ventila-
tion has been shown to significantly improve survival
in DMD patients from the late teens to the mid-late
thirties [12–15]. Given the increasing amount of drugs
in a clinical test phase, in depth information of the
natural history of DMD patients has become of increas-
ing interest. In the Netherlands, a database containing
extensive information of Dutch Duchenne and Becker
muscular dystrophy (BMD) patients was set up in
Leiden in 2008, as part of the TREAT-NMD patient
registry initiative. As genetic diagnostics for DMD are
centralized in Leiden, there is a good overview of the
size of the Dutch DMD population. Currently, over
70% of known DMD patients have been registered in
the Dutch Dystrophinopathy Database (DDD). There-
fore, the Dutch database provides an excellent oppor-
tunity to present a study of the natural history of DMD.
In the current study, we provide a detailed
population-based description of the disease course of
DMD in the Netherlands. To further investigate the
effect of developments in care for DMD patients, we





Patients were selected from the DDD. Recruitment
was achieved through the Dutch patient organizations
‘Duchenne Parent Project’ and ‘Dutch Association for
Neuromuscular Diseases’, physicians (paediatricians,
(paediatric)neurologists, rehabilitation specialists, car-
diologists, geneticists and physicians working at the
four centers for home mechanical ventilation), inter-
net (www.lumc.nl/duchenne) and an advertisement
in a national glossy. Information about deceased
patients was gathered through family members. Writ-
ten informed consent was provided by all patients or
their legal representatives. The study was approved by
the medical ethical committee of the Leiden University
Medical Center.
Inclusion criteria for the present study were: males
born between 1980 and 2006 with a definite diagnosis
of DMD, as defined by progressive muscle weakness
and
1) an out-of-frame deletion or duplication in the
DMD gene, or
2) a small deletion/insertion or point mutation in the
DMD gene resulting in a premature stopcodon,
or
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3) a combination of other mutations in the DMD
gene (in-frame mutations, splice-site mutations)
known to cause a severe clinical phenotype as
registered in the Leiden Open Variation Database
(LOVD) AND age at wheelchair dependence
before the age of 13, or
4) absence of dystrophin on immunohistochemistry
staining of the muscle biopsy.
The 1980 limit was chosen to facilitate comparison
with the 1961–1974 cohort by leaving out an arbitrary
number of five years (1975–1979) in between the two
cohorts. Patients born after 2006 were excluded since
at the time of reviewing the data these patients were too
young to provide information about the studied disease
milestones.
Cohort 2 (1961–1974)
To evaluate the long term effects of the developments
in care, data were compared to those of Dutch DMD
patients born between 1961 and 1974 as described pre-
viously by Van Essen et al. [16]. From this historical
cohort only patients with definite DMD, as defined by
Van Essen et al. were selected [17]. This definition
was based on a scoring system involving data regarding
clinical picture, creatine kinase level, electromyogram,
muscle biopsy, electrocardiogram and inheritance.
Medical history
Information on disease course was provided by
patients and their caretakers through a standardized
questionnaire. Self-reported information was gathered
about height and weight, education, age at diagno-
sis, age at loss of ambulation, occurrence of scoliosis
surgery and age at surgery, age at start of mechanical
ventilation, use of corticosteroids and cardiac medica-
tion and age at death. Z-scores for height and BMI were
calculated using standards for Dutch boys as published
by Fredriks et al. [18, 19].
Cardiac analysis
Written reports on echocardiographic studies were
retrieved from (paediatric)cardiologists concerned
with the care of DMD patients. Our analysis was
focussed on the left ventricular fractional shortening
(FS) as this provides an important measurement of the
existence and severity of a cardiomyopathy. Addition-
ally the FS was considered relatively robust, given the
fact that patients were seen in different centres over
the years. Cardiomyopathy was defined as a FS ≤27%
[20].
DNA analysis
Information about mutational analysis was retrieved
from the department of Clinical Genetics of Lei-
den University Medical Center, where all analyses on
Dutch patients had been performed. DNA analysis was
performed as previously described by Van den Bergen
et al. and Almomani et al. [21, 22].
Statistical analysis
Mean/median age at reaching the different disease
milestones was estimated using a Kaplan Meier Sur-
vival Analysis. Differences in patient characteristics
between steroid treated and steroid naı¨ve patients were
calculated using the Students’ T-test. Differences in
ages at wheelchair dependence between different sites
of mutation as well as steroid use were calculated
with a Kaplan Meier Survival Analysis using the Log
Rank Test. The correlations between birth year and
age at diagnosis, between the age at reaching the
different disease milestones and between the age at
first cardiac examination and Fractional Shortening
were calculated using Pearson’s Correlation Coeffi-
cient. Significance level for all analysis was set at




The DDD contains 462 patients with a clinical diag-
nosis of DMD, of whom 377 have a DNA-confirmed
diagnosis. Three-hundred thirty-six patients met our
inclusion criteria. Number of patients per year of birth
ranged from 7 (1984) to 24 (1996) (Fig. 1). Forty-one
patients had died at the time of the study, at a mean
age of 19 years (±5.6). Mean age of patients that were
still alive was 15 years (±6.6). The standardized height
corrected for age of patients still alive was below the
average of the general Dutch male population (z-score
−0.75) for both steroid users and non-users, while
BMI was above average (z-score 0.92). See Table 1
for patient characteristics.
Disease course
In our cohort the mean age at diagnosis was 4.3 years
(±2.2). Two-hundred-fifteen patients had become
wheelchair dependent at a mean age of 9.7 years
(±1.8). When including the still ambulant patients,
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Fig. 1. Study population. Included DMD patients categorized by year of birth for both the historical (1961–1974; n = 293) and the present cohort
(1980–2006; n = 336). The white part of the columns represent DNA-confirmed DMD patients not participating in the present study. For the
historical cohort, these data were not available.
Table 1
Characteristics of the 1980–2006 study population for all patients together, as well as separately for steroid-treated and steroid-naı¨ve patients.
Of 21 patients steroid use was unknown
All patients (n = 336) Steroid-treated patients (n = 165) Steroid-naı¨ve patients (n = 150)
n Mean (SD) n Mean (SD) n Mean (SD) p-value
Year of birth 336 1994 (7.1) 165 1998 (4.3) 150 1990 (6.6) <0.001
Age (years) 295 15 (6.6) 165 12 (4.3) 124 20 (6.6) <0.001
Height (z-score) 224 −0,75 (1.4) 140 −0.53 (1.3) 83 −1.12 (1.5)
BMI (z-score) 201 0.92 (1.5) 140 1.2 (1.4) 60 0.37 (1.6)
Age at death (years) 41 19 (5.6) 0 – 26 19 (5.9)
Percentage Percentage Percentage
Chronic Pain 241 23 143 19 97 29
Fractures 256 33 150 25 105 45
Use of laxatives 256 27 149 22 106 36
PEG tube 241 23 148 1 103 11
the median estimated time to wheelchair dependence
was 10.0 (±0.16) years. Information about scolio-
sis surgery was present for 315 patients, of whom
102 patients (32%) had scoliosis surgery, at a mean
age of 14 years (±2.1). Mechanical ventilation (day
and/or night) was initiated in 93 patients at a mean
age of 17 years (±3.7), of whom 17 patients had a
tracheostomy, while 31 patients used a mouthpiece
and/or (oro)nasal mask. Of the other 43 patients the
form of mechanical home ventilation was not known.
The median age of survival without mechanical venti-
lation was 20 years (±0.53). Patients who had scoliosis
surgery used mechanical ventilation at a significantly
younger age than patients who did not have scoliosis
surgery (18 versus 23 years;P < 0.001). This difference
remained significant when excluding steroid-treated
patients. Age at wheelchair dependence predicted the
age at scoliosis surgery and age at start of ventilatory
support: patients who lost ambulation at a younger
age also had scoliosis surgery at a younger age (R
0.54 P 0.0003) and used ventilatory support earlier (R
0.57 P < 0.0001). This correlation remained significant
when correcting for steroid use (P 0.001 and P < 0.001
resp). The mean age at death of the 41 deceased patients
was 19 years (±5.6), whereas the estimated mean age
of survival was 27 years (±0.49). Causes of death were
not provided. Figure 2 shows the range of ages at which
all disease milestones were reached.
Education
Data about education was present for 247 patients
(74%). One-hundred-fifteen patients (47%) attended
a regular elementary school, while 78 patients (32%)
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Fig. 2. Disease milestones in DMD. Age at which disease milestones are reached for the 1980–2006 cohort. The continuous lines represent the
age at which patients reached the specific milestone, while the dotted lines represent the current ages of patients who have not yet reached the
milestone.
attended a school for chronically ill children. Fifty-four
patients attended a school for children with behavioural
difficulties or attended multiple types of schools con-
secutively. There was a difference in educational
level at secondary school when comparing our DMD
cohort with the general Dutch population (Practical
education 16% versus 9%, Lower general secondary
education 43 versus 24% and Higher general sec-
ondary education/Pre-University education 41 versus
17%; data provided by Statline, Statistics Netherlands,
www.cbs.nl). Twenty-four patients older than twelve
years (21%), did not attend any secondary school. Of
the 51 patients over 18 years of age of whom data about
education was available only 17 (31%) followed voca-
tional/college/university training. See Table 2 for all
data about education.
Cardiac analysis
Data regarding fractional shortening was present
for 133 patients, of which 97 patients had multi-
ple measurements (range 2–20). Median age at first
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Table 2
Educational level of the 1980–2006 DMD cohort
Educational level n %
Elementary School
1. Regular elementary school 115 46
2. School for chronically ill children 78 32
3. School for children with behavioural difficulties 7 3
4. Multiple schools (1&2 or 1&3) 47 19
Secondary School (pt > 12yrs)
1. Practical education 18 16
2. Lower general secondary education 48 43
3. Higher general secondary education 12 11
4. Pre-university education 7 6
5. Other 4 4
6. None 24 21
Professional Education (pt > 18yrs)
1. Vocational education 15 29
2. University of Applied Sciences 1 2
3. University 1 2
4. None 34 67
analysis was 8 years (range 3–26). There was a
significant negative correlation between age at first
examination and FS (R −0.64 P < 0.0001), indicat-
ing the progressive nature of cardiac involvement in
DMD (Fig. 3A). Survival analysis showed an esti-
mated mean time to cardiomyopathy of 16.4 years (FS
≤27) (Fig. 3B). Data concerning cardiac medication
was present for 269 patients. Of those 49 (17%) used
cardiac medication: 41 (84%) an ACE-inhibitor, 18
(37%) a beta-blocker, 10 (20%) a diuretic and 4 patients
(8%) an angiotensin-II-antagonist. Only three patients
used oral anticoagulation and two patients an anti-
arrhythmic agent. Median age of patients on cardiac
medication was 18.5 years (range 5–29).
Corticosteroids
One-hundred-sixty-five patients (49%) used
steroids at some point, of whom 46 (14%) had ceased
to use steroids at the time of the study. In 21 patients
steroid use was unknown. The mean age at start of
steroid use was 6.5 years, while mean age at which
patients ceased steroid use was 9.5 years. The steroid
treated patients were significantly younger than the
steroid naı¨ve patients (mean age 12 versus 20 years;
P < 0.001) (Table 1). Fig. 4 represents the percentage
of steroid users per birth year. To investigate the possi-
ble effect of steroids on age at wheelchair dependence
patients were divided into two groups: 1) patients who
did not use steroids prior to wheelchair dependence
(n = 175) 2) patients who started using steroids at least
two years before losing ambulation and continued
steroids for at least one year (n = 99). Patients who
Fig. 3. Echocardiographic examination of DMD patients in the
1980–2006 cohort. A. Fractional Shortening of patients at first
echocardiographic examination (n = 133). The dotted line represents
a fractional shortening of 27%, often used as the cut-off value to diag-
nose a cardiomyopathy. B. Survival analysis for cardiomyopathy, as
defined by a fractional shortening equal to or less than 27% (n = 108).
had used steroids for less than one year or who started
less than two years before loss of ambulation, as
well as patients who could not be classified (n = 62)
were excluded. The limits were chosen to ensure
that steroid use had been long enough to influence
ambulation. The effect of steroid use on the other
disease milestones could not be analysed, as too few
patients in the steroid treated group had reached these
milestones (scoliosis surgery 14/122, mechanical
ventilation 9/120, death 0/124). As expected, use of
steroids had a positive effect on ambulation: median
age at wheelchair dependence increased from 10 years
to 11 years (P < 0.001) in steroid treated compared to
steroid-naı¨ve patients (Fig. 5).
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Fig. 4. Percentage of steroid users among DMD patients per year
of birth. The light columns represent patients who previously used
steroids, but have ceased to do so, the dark columns represent patients
currently using steroids.
Fig. 5. Kaplan Meier Survival Curve for age at wheelchair depen-
dence for steroid-treated (dotted line) and non-treated (black line)
patients in the 1980–2006 cohort.
Mutation analysis
A deletion of one or several exons was present
in 212 patients, of whom 204 had an out-of-frame
deletion. The eight patients with an in-frame deletion
presented with a severe phenotype conform the inclu-
Fig. 6. Kaplan Meier Survival Curve of age at loss of ambulation
(A) and age at death (B) for all patients from the 1961–1974 and
1980–2006 birth cohorts.
sion criteria. A duplication was found in 42 patients,
a premature stopcodon in 49 and splice-site muta-
tions in 18 patients. Of 12 patients the exact mutation
was not known. Three patients were diagnosed on the
basis of the absence of dystrophin staining in a mus-
cle biopsy. Most mutations (n = 243) were located in
the central rod domain (exons 8–61), while 21 muta-
tions involved only the actin binding site (exons 2–8).
Thirty-three mutations involved both the actin binding
site and the central rod domain. Mutations at the 3′-end
of the DMD gene were rare: only 4 patients presented
with a mutation in the cysteine-rich domain (exons
63–69) and 3 patients with a mutation in the carboxy-
terminal domain (exons 70–79). In one patient the
mutation involved both these regions (an exon 61–76
deletion).
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Comparison with cohort 1961–1974
Data were present for 293 DMD patients born
between 1961 and 1974. The median birth year was
1968. Number of patients per year ranged from 9
(1972) to 28 (1968) (Fig. 1). Ninety-eight patients had
died at the time of data collection in 1998.
Mean age at diagnosis for the 1961–1974 cohort was
5.3 years (±2.2). There was a significant correlation
between year of birth and age at diagnosis (R −0.32
P < 0.001). Data about wheelchair use were present
for 248 patients, of whom 232 where wheelchair
dependent. The mean age at loss of ambulation for
these patients was 8.9 years (±2.7). When compar-
ing age at wheelchair dependence between the two
cohorts, patients born between 1980 and 2006 lost
ambulation at a significantly later age than those born
between 1961 and 1974 (survival-analysis 10.4 versus
9.6 years P < 0.001) (Fig. 6A). Interestingly, this dif-
ference remained significant when excluding steroid
treated patients (9.8 versus 9.6 years P 0.046). No com-
parison for steroid treated patients was possible, since
none of the patients in the 1961–1974 cohort had used
steroids. The mean age at death of the 98 deceased
DMD patients in the 1961–1974 cohort was 16 years
(±2.9). Mean survival was significantly higher in the
1980–2006 cohort than in the 1961–1974 cohort (27.3
versus 17.7 years P < 0.001) (Fig. 6B). No informa-
tion about scoliosis surgery, mechanical ventilation or
education was present for this cohort.
DISCUSSION
In the current study we present detailed clinical
information about a large Dutch DMD cohort and com-
pare this information with an historical Dutch DMD
cohort. Several studies regarding disease course in
DMD have been published, but often cover only a
small part of all patients in a country or region. Our
data present a cohort from one and the same country
including more than 70% of all Dutch DMD patients.
Comparison of the present cohort with the historical
data revealed several improvements in diagnosis and
care. First of all, mean age at diagnosis decreased from
5.3 years historically to 4.3 years. This age is in accor-
dance with previous (smaller) studies, showing mean
ages at diagnosis between 3.2 and 4.8 years of age
[23–26]. Interestingly, most of this decrease occurred
before the introduction of standard DNA-diagnostics
for DMD in the Netherlands, illustrating the power of
clinical diagnosis of DMD and the possible increasing
awareness of the diagnosis.
Although diagnosis is made at a younger age, there
is still time to gain in diagnosing DMD, both to pro-
vide good care for the patient in question as well as to
counsel the parents regarding further family planning.
With the development of therapies, early diagnosis will
become increasingly important.
Secondly, we noticed a prolonged survival in the sec-
ond cohort. Dutch patients born in the 1960 s hardly
ever reached the age of 20 years (15%), while this
improved to 89% for patients born in the 1980 s. The
mean survival has improved with 10 years. This change
is mostly due to the introduction of mechanical ventila-
tion in the late 1980 s, which in two large studies have
shown to increase survival with 6 to 20 years [12, 27].
We were unable to investigate the effect of steroid use
on survival, as steroids were only prescribed routinely
in the Netherlands since 2005. Previous smaller stud-
ies, however, showed a clear positive effect of steroid
use on age at start of mechanical ventilation [4–11]. It
would be of great interest to confirm these results in a
large population based study.
Next, when comparing our cohort to the historical
cohort, there is a significant later age at wheelchair
dependence. This difference is mostly due to the intro-
duction of steroids. In our cohort there was a significant
effect of steroid use on ambulation, retaining ambula-
tion for an average of nearly two years. Interestingly,
when excluding all steroid treated patients, a small (2-3
months) but significant difference in age at wheelchair
dependence still remained. This might represent the
effect of improvements in care, like the use of more
advanced walking aids, prevention by splints, more
consistent use of physiotherapy and Achilles tendon
lengthening.
In our cohort, survival analysis of age at wheelchair
dependence showed a mean age of 10.4 years. This is in
concordance with a previous report by Magri et al. but
somewhat higher than other reports [12, 27–30]. This
difference might be explained by different percentages
of steroid users between these cohorts. As previously
reported, age at wheelchair dependence was positively
correlated with age at scoliosis surgery and start of
mechanical ventilation [29, 31, 32]. This indicates that
the disease course of some patients is more severe.
Alternatively, it could be that there is a protective effect
of maintenance of ambulation on disease progression.
In our cohort, 32% of patients had scoliosis surgery,
at a mean age of 14 years (46% when excluding patients
<12 years). When comparing different cohort studies
in DMD, these percentages vary greatly, ranging from
4 to 77% [31–34]. There are several factors that could
contribute to these differences. Firstly, indications for
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scoliosis surgery vary between different countries and
also have changed in the last decades. Furthermore,
not having scoliosis surgery does not necessarily mean
a milder scoliosis, as in some cases there are contra-
indications for surgery (most importantly a decreased
pulmonary function and the presence of a cardiomy-
opathy) [26]. Lastly, several studies have shown steroid
use to reduce the number of scoliosis surgeries [5, 7,
8, 10, 26]. As the percentage of steroid users might
vary between the different studies, this could influence
the total number of surgeries within the cohorts. In our
DMD cohort, patients who had scoliosis surgery were
in need of mechanical ventilation at a significantly
younger age than patients who did not have surgery.
Several previous studies found a trend showing sco-
liosis surgery being correlated with a faster decline
of Forced Vital Capacity (FVC) or a younger age at
start of mechanical ventilation [31, 32, 35]. Again,
this could be explained by the possibility that scoliosis
surgery is one of the markers of a more progressive
disease.
Cardiac analysis showed presence of a cardiomy-
opathy in 35% of patients. The estimated mean time
to cardiomyopathy was 16.4 years. Unfortunately, due
to heterogeneity of our steroid data, we were unable to
investigate the possible effect of steroids on the devel-
opment of cardiomyopathy. Previous reports, however,
have shown a positive effect of steroids on cardiac func-
tion [10, 11, 36, 37]. In our cohort, steroid use was
associated with an increase in BMI, but no reduced
growth, when compared to steroid naı¨ve patients. Most
Dutch patients on steroids (>80%; data not shown) use
a 10-days-on-10-days-off regimen [38]. Previous stud-
ies have shown that this regimen has less deleterious
effects on growth and weight than the daily regimen
[39, 40]. Our study confirms the limited effect of this
regimen on growth.
Our study has several limitations. Firstly, our data
represent about 70% of the Dutch DMD population.
Although this is a large percentage, there still is the
possibility of a selection bias. Most importantly, there
could be an underrepresentation of patients with a
severe disease course, who might have died at an
early age. However, through the involvement of patient
organisations, media and specific information for sur-
viving relatives of deceased patients, we have spent
much effort into including these patients as well.
A second limitation of our study is the strict use
of inclusion criteria for the diagnosis of DMD. Espe-
cially in the 1980s, when DNA-diagnostics were not
available, diagnosis of DMD was based on clinical
characteristics, combined with high CK-levels and
an X-linked inheritance. Therefore, it could be that
some patients were erroneous excluded from the study.
Lastly, only younger patients in our cohort have been
treated with steroid. Therefore, the effect of steroid use
on disease milestones like mechanical ventilation and
age at death could not be compared between the two
cohorts.
In conclusion, our study presents important data
about the current disease course of the Dutch popu-
lation of DMD patients, supporting the positive effect
of steroid use on delay of disease progression and of
mechanical ventilation on survival. Interestingly, we
also found a discrete positive effect of improvements
in standards of care on age at wheelchair dependence.
These findings emphasize that databases like the DDD
are of great importance, not only as a resource for future
trials, but also to evaluate the effect of developments
in care and treatment.
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